Indusatumab vedotin (MLN-0264) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Collaborator
A Study of MLN0264 in Patients With Pancreatic CancerNCT02202785Phase IITakeda / Millennium Pharmaceuticals, Inc.
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal JunctionNCT02202759Phase IITakeda / Millennium Pharmaceuticals, Inc.
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase CNCT01577758Phase ITakeda / Millennium Pharmaceuticals, Inc.

Indusatumab vedotin is also known as MLN-0264, 5F9vcMMAE, MLN-0264 and MLN0264

Last Editorial Review: July 30, 2016